Antimicrobial wound dressings are a minefield if you don't know what you are doing
I have spent the better part of two decades working in wound care product development and clinical evaluation. The industry is full of marketing spin, but the actual science of keeping a wound free from infection while it heals is nuanced and often frustrating. Scott Borgerson has been one of the more persistent voices pushing for real innovation in this space, particularly around silver-based antimicrobial technologies and how they interact with different wound types. His work at Advanced Bioheat Solutions and earlier ventures touched on things most companies gloss over: the difference between ionic and colloidal silver delivery, cytotoxicity thresholds, and why a dressing that looks great in a petri dish falls apart in a chronic ulcer patient. Here is the practical reality. Most wounds that refuse to heal do so because of biofilm formation. A biofilm is a structured community of bacteria encased in a self-produced polymer matrix. It is not just germs sitting on the surface. It is a fortress. Standard silver dressings often fail against established biofilms because the silver ions cannot penetrate the matrix at effective concentrations. Borgerson's approach emphasized controlled release mechanisms and substrate engineering that allowed sustained antimicrobial activity without the spike-and-crash concentration profiles most competitive products produce. The core concept is simple on paper but hard to execute. You need a delivery system that releases silver at a rate matching the wound exudate load. Too fast and you kill fibroblasts. Too slow and you cannot breach the biofilm. I worked with a product based on one of his earlier design philosophies on a research contract a few years back. We were testing it against diabetic foot ulcers with moderate exudate. The initial results looked promising. Then we hit a subset of patients with heavily macerated periwound skin and high bioburden. The dressing lifted at the edges within forty-eight hours because the adhesion layer was not designed for that moisture profile. We ended up using a secondary silicone border dressing underneath and it stabilized everything. That workaround became standard protocol for our trial. It was not in the original instructions.
The cytotoxicity issue is the thing most people miss. Silver is broadly antimicrobial, which means it does not distinguish between Pseudomonas and your patient's keratinocytes. Several early-generation silver dressings had measurable cytotoxic effects at concentrations that were still considered "therapeutic." Borgerson's later work focused on lowering the free silver ion concentration below the cytotoxic threshold while maintaining antimicrobial efficacy through prolonged exposure time. It is a different pharmacokinetic model. Instead of hitting hard and fast, you maintain a low steady state. Clinical studies support this. It just means you need to leave the dressing in longer than some manufacturers recommend. Changing it every two days defeats the mechanism. There is also the question of substrate. Silver on nylon behaves differently than silver on hydrofiber or silver on silicone mesh. The ion release kinetics shift depending on the carrier material's water content and porosity. I have seen wound care teams apply the same dressing to two adjacent wounds on the same patient and get completely different outcomes because one wound had slough and the other was granulating. The slough wound consumed the available silver through protein binding within hours. The granulating wound went unmedicated by day three. You have to match the dressing type to the wound bed phenotype, not just the diagnosis. Another counter-intuitive point: silver resistance is real but rare in clinical practice. Most reports of silver-resistant organisms come from industrial or environmental settings where bacteria are exposed to sub-lethal silver concentrations continuously over generations. In wound care, the exposure is intermittent and the bacterial load is far lower. What actually happens more often is that non-silver-resistant bacteria get eliminated and pre-existing resistant strains like MRSA or VRE become the dominant population by selective pressure. It is not resistance developing. It is resistance being selected for. This is why rotation of antimicrobial agents or combining silver with other modalities like medical-grade honey or polyhexanide can be strategically useful in recalcitrant wounds.
The downside of Borgerson's approach and controlled-release silver systems in general is cost and availability. These products are significantly more expensive than basic hydrocolloids or foam dressings. Insurance coverage varies widely by payer and region. A single dressing can run forty to eighty dollars depending on size and technology. For outpatient wound care clinics managing high volumes of venous leg ulcers, that adds up fast. Some health systems have responded by restricting these dressings to cases where conventional therapy has failed after a defined trial period. That is reasonable from a cost perspective but it means patients wait longer before getting the more effective intervention. If you are evaluating whether to adopt any of the technologies associated with Borgerson's innovations, here is what I would tell you. Start by testing the product on a small cohort of your most challenging wounds. Track time to reduction in bioburden, not just time to healing. Healing is a distant endpoint. Bioburden reduction happens in days. You will get feedback faster. Pay attention to periwound skin integrity. Silver dressings can cause argyria-like discoloration or contact dermatitis in a small percentage of patients. Document it. Also measure exudate volume before and after switching. If the dressing is managing moisture well while delivering antimicrobial action, you should see a correlating decrease in change frequency. If you are still changing it daily, the controlled-release mechanism is not engaging properly and you are paying for a technology you are not using. One final practical note. The literature on silver wound dressings is messy. Many systematic reviews conflate different silver types, different carriers, and different clinical indications into single conclusions. When you read a study claiming "silver dressings are ineffective" or "silver dressings are superior," check what specific product was tested and against what comparator. A study showing no benefit using a low-dose silver nylon dressing on a superficial abrasion tells you almost nothing about a high-load silver hydrofiber on a stage three pressure injury. Context matters more than the headline result.
Get the Full Details
